Rubicon Research Q2 FY27 Share Price & Earnings Call Analysis
Part of: Nifty Smallcap 250 · Nifty MidSmallcap 400 · Nifty 500 · Nifty Total Market
- Market cap
- ₹27,778 Cr
- P/E
- 85.51
- ROE
- 26.96%
- PEG
- 0.55
- Price to sales
- 13.22
- Debt to equity
- 0.35
- 52W high / low
- ₹1,861 / ₹615
- Sales growth (5Y)
- 41.00%
- EBITDA margin
- 23.81%
- Net profit margin
- 14.06%
- Promoter holding
- 51.25%
- Sales (last year)
- ₹2,100 Cr
Incorporated in 1999, Rubicon Research Limited is a pharmaceutical company engaged in the development, manufacturing, & commercialization of differentiated formulations.[1]
Guidance scorecard · Q2 FY27 call
What Rubicon Research's management guided
and where it ranks in Pharmaceuticals & Biotechnology
Pharmaceuticals & Biotechnology
RevenueQ2 FY27 call
10–20%- Sequential USD revenue growth was 5% in the recent quarter with strong visibility for upcoming quarters.
- Focus on steady ramp-up of new products ensuring stable margins; specialty/differentiated products contributing significantly to gross profit.
- Revenue growth is expected through commercialization of products and regulatory approvals, with licensing processes recently updated.
- R&D productivity has improved significantly, with a 5.9x incremental revenue growth against R&D spend expected by FY 2027, indicating strong revenue growth visibility for FY 2029, FY 2030, and beyond.
- Three pre-revenue manufacturing facilities (Indore, CSN, New Jersey) expected to start contributing by FY 2028 onwards, providing further growth potential.
2 more points from Rubicon Research's call on revenue
Create a free account to keep reading this call
MarginsQ2 FY27 call
FlatSee what Rubicon Research said on margins — free account, 30 seconds.
CapexQ2 FY27 call
Planned- Capex driven by acquisition of Arinna Lifesciences and New Jersey-based manufacturing facility.
- Fixed asset base grew by INR 85 crores for New Jersey facility; cash payout was INR 29 crores; INR 55 crores non-cash right-of-use.
- Capital employed includes nearly INR 400 crores (25% of total capital) in pre-revenue assets such as Pithampur, Chhatrapati Sambhajinagar (Aurangabad), New Jersey facility, and Arinna Lifesciences.
2 more points from Rubicon Research's call on capex
Create a free account to keep reading this call
FundraisingQ2 FY27 call
See what Rubicon Research said on fundraising — free account, 30 seconds.
Order bookQ2 FY27 call
Ask what Rubicon Research said on the order book →
Full Q2 FY27 analysisRanges are what management guided for revenue growth and margins on the latest earnings call. Not investment advice, and not a forecast of returns.
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Rubicon Research latest results (Sep 2026)
Revenue
₹576 Cr
+40% YoY
Net profit
₹90 Cr
+67% YoY
Operating margin
25%
EPS
₹5.47
Rubicon Research shareholding (Sep 2026)
Promoters
51.25%
−8.51 pp QoQ
FIIs
9.01%
+1.49 pp QoQ
DIIs
15.73%
+6.30 pp QoQ
Public
24.03%
+0.74 pp QoQ
Peers
Pharmaceuticals & Biotechnology companies ranked on guidance
| # | Company | Revenue guided | Margin guided | Market cap | P/E |
|---|---|---|---|---|---|
| 1 | 40%+ | Up 2%+ | ₹3,041 Cr | 33.1 | |
| 2 | 40%+ | Up 2%+ | ₹492 Cr | 19.6 | |
| 3 | 40%+ | Up 0–2% | ₹234 Cr | 17.8 | |
| 4 | 40%+ | Flat | ₹18,347 Cr | — | |
| 5 | 40%+ | Flat | ₹8,432 Cr | 32.4 | |
| 6 | 40%+ | Flat | ₹4,295 Cr | — |
Sign up free to see every company in the sector ranking and track Rubicon Research.
Pro shows every company guiding 40%+ revenue growth →Full Pharmaceuticals & Biotechnology rankingRubicon Research announcements
All announcements →- Acquisition / mergerNotableRubicon Research Limited completes acquisition of 85% stake in Arinna Lifesciences Limited
Financials of Rubicon Research
Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.
Shareholder Pattern
Rubicon Research
Shareholding breakup across reporting periods.
| Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | |
|---|---|---|---|---|
| Promoters + | 59.99% | 59.86% | 59.76% | 51.25% |
| FIIs + | 7.99% | 7.54% | 7.52% | 9.01% |
| DIIs + | 9.45% | 10.02% | 9.43% | 15.73% |
| Public + | 22.57% | 22.57% | 23.29% | 24.03% |
| No. of Shareholders | 31,914 | 33,738 | 43,254 | 38,018 |
Financials of Rubicon Research
Quarterly Results
Quarter-by-quarter operating performance
| Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|
| Sales + | 296 | 313 | 358 | 352 | 412 | 476 | 514 | 534 | 576 |
| YoY Sales growth | +39% | +52% | +43% | +52% | +40% | ||||
| Expenses + | 234 | 244 | 286 | 273 | 318 | 367 | 395 | 405 | 432 |
| Operating Profit | 62 | 70 | 72 | 79 | 94 | 108 | 119 | 129 | 144 |
| OPM % | 21% | 22% | 20% | 22% | 23% | 23% | 23% | 24% | 25% |
| Other Income + | 3 | 0 | 0 | 1 | 1 | 4 | 3 | 6 | 2 |
| Interest | 7 | 8 | 12 | 11 | 11 | 10 | 10 | 9 | 11 |
| Depreciation | 8 | 9 | 10 | 10 | 12 | 12 | 12 | 15 | 18 |
| Profit before tax | 49 | 53 | 51 | 60 | 72 | 91 | 99 | 110 | 117 |
| Tax % | 30% | 28% | 29% | 27% | 25% | 20% | 22% | 23% | 23% |
| Net Profit + | 34 | 38 | 36 | 43 | 54 | 73 | 77 | 85 | 90 |
| EPS in Rs | 2.27 | 2.50 | 2.35 | 2.81 | 3.49 | 4.42 | 4.65 | 5.13 | 5.47 |
Financials of Rubicon Research
Profit & Loss
Annual income statement trend
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|
| Sales + | 263 | 315 | 314 | 394 | 854 | 1,284 | 1,754 | 2,100 |
| Sales growth | +20% | -0% | +26% | +117% | +50% | +37% | +46% | |
| Expenses + | 182 | 223 | 353 | 375 | 699 | 1,020 | 1,354 | 1,600 |
| Operating Profit | 81 | 92 | -39 | 18 | 155 | 264 | 400 | 500 |
| OPM % | 31% | 29% | -12% | 4.7% | 18% | 21% | 23% | 24% |
| Other Income + | 18 | 10 | 17 | 25 | 18 | 4 | 8 | 14 |
| Interest | 6 | 9 | 10 | 19 | 31 | 37 | 42 | 41 |
| Depreciation | 18 | 29 | 34 | 36 | 39 | 37 | 45 | 57 |
| Profit before tax | 74 | 63 | -66 | -11 | 103 | 195 | 321 | 417 |
| Tax % | 33% | 51% | 2% | 53% | 12% | 31% | 23% | |
| Net Profit + | 49 | 31 | -67 | -17 | 91 | 134 | 247 | 325 |
| EPS in Rs | 3.25 | 2.02 | -4.42 | -1.11 | 5.98 | 8.72 | 14.95 | 19.67 |
| Dividend Payout % | 2% | 2% | -0% | -2% | 0% | 0% | 10% |
Financials of Rubicon Research
Balance Sheet
Capital structure and asset base
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|
| Equity Capital | 5 | 5 | 5 | 5 | 15 | 15 | 17 | 17 |
| Reserves | 335 | 369 | 300 | 281 | 370 | 526 | 1,272 | 1,400 |
| Borrowings + | 30 | 93 | 175 | 320 | 425 | 418 | 311 | 501 |
| Other Liabilities + | 60 | 71 | 79 | 144 | 300 | 493 | 727 | 843 |
| Total Liabilities | 430 | 538 | 560 | 750 | 1,109 | 1,451 | 2,327 | 2,761 |
| Fixed Assets + | 157 | 188 | 193 | 199 | 307 | 327 | 532 | 803 |
| CWIP | 2 | 6 | 3 | 25 | 10 | 7 | 41 | 90 |
| Investments | 19 | 14 | 0 | 0 | 0 | 0 | 27 | 29 |
| Other Assets + | 252 | 330 | 364 | 526 | 793 | 1,118 | 1,728 | 1,839 |
| Total Assets | 430 | 538 | 560 | 750 | 1,109 | 1,451 | 2,327 | 2,761 |
Financials of Rubicon Research
Cash Flows
Operating, investing and financing cash movement
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Cash from Operating Activity + | 5 | 62 | -63 | -75 | 21 | 159 | 205 |
| Cash from Investing Activity + | -84 | -46 | -46 | -32 | -68 | -65 | -407 |
| Cash from Financing Activity + | 80 | 52 | 63 | 123 | 44 | -40 | 283 |
| Net Cash Flow | 1 | 67 | -45 | 16 | -4 | 54 | 81 |
| Free Cash Flow | -54 | -10 | -117 | -119 | -35 | 91 | -24 |
| CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit | 40% | 104% | 138% | -394% | 25% | 75% | 78% |
Financials of Rubicon Research
Ratios
Working capital efficiency and return ratios
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Debtor Days | 194 | 158 | 162 | 209 | 129 | 92 | 106 |
| Inventory Days | 360 | 508 | 502 | 609 | 428 | 574 | 550 |
| Days Payable | 183 | 271 | 320 | 353 | 252 | 263 | 285 |
| Cash Conversion Cycle | 371 | 395 | 345 | 465 | 305 | 403 | 371 |
| Working Capital Days | 183 | 149 | 107 | 75 | 57 | 46 | 104 |
| ROCE % | 17% | -12% | 1% | 19% | 26% | 28% |
Guidance history
How Rubicon Research's guidance has moved, call by call
| Call | Revenue | Margins | Capex | Fundraising | Order book |
|---|---|---|---|---|---|
| Q2 FY27 call → | 10–20% | Flat | Planned | — | — |
| Q1 FY27 call → | 20–40% | Flat | Planned | — | — |
| Q4 FY26 call → | 20–40% | Flat | Planned | Planned | — |
| Q3 FY26 call → | 20–40% | Flat | Planned | — | — |
What management guided on each call, newest first. Not investment advice, and not a forecast of returns.
Momentum score · price trend
90 out of 100 — Strengthening
Over the past year its share price has done better than most of the stocks we track.
| Period | Share price change | Better than … of 1,938 stocks |
|---|---|---|
| Last 12 months | +156.3% | 97% |
| Last 6 months | +74.5% | 94% |
| Last 3 months | +3.6% | 68% |
How we calculate it
“Better than 30%” means that over that period the share price did better than 30 out of every 100 stocks we track (1,938 Indian companies worth ₹500 Cr or more, with at least a year of prices).
The score weighs the longer periods more: 40% × 12-month + 40% × 6-month + 20% × 3-month. For Rubicon Research: 0.4 × 97 + 0.4 × 94 + 0.2 × 68 = 90.
Strengthening is 70 and above, Steady 40 to 70, Cooling below 40. Scores are recalculated every night after the market closes.
Full methodology →This describes only how the share price has moved up to 13 Nov 2026, compared with other stocks. It says nothing about the business, and it is not a prediction, a price target or a recommendation to buy or sell.
Rubicon Research: frequently asked questions
What is Rubicon Research share price today?
Rubicon Research last traded at ₹1,677.2, with a market capitalisation of ₹27,778 Cr and a P/E ratio of 85.5.
What were Rubicon Research's latest quarterly results?
For the quarter ended Sep 2026, Rubicon Research reported revenue of ₹576 Cr (+40% year on year) and net profit of ₹90 Cr, with an operating margin of 25%.
Is Rubicon Research's profit growing?
Net profit was ₹90 Cr in Sep 2026 against ₹54 Cr in Sep 2025, a change of +67%.
What is Rubicon Research's EPS?
Rubicon Research's earnings per share for the quarter ended Sep 2026 was ₹5.47.
What is the promoter holding in Rubicon Research?
Promoters held 51.25% of Rubicon Research in Sep 2026 (−8.51 pp versus Jun 2026).
How much do FIIs and DIIs hold in Rubicon Research?
In Sep 2026, foreign institutional investors held 9.01% and domestic institutions (including mutual funds) held 15.73% of Rubicon Research.
What is Rubicon Research's ROE and ROCE?
Rubicon Research's return on equity is 27% and its return on capital employed is 28.4%.
Does Rubicon Research pay a dividend?
Yes. Rubicon Research's dividend yield is 0.09% at the current price. The full payout history is on the Rubicon Research dividends page.
Which sector does Rubicon Research belong to?
Rubicon Research is in the Pharmaceuticals & Biotechnology sector. Its peer comparison and sector ranking are on this page.
What did Rubicon Research's management say on the latest earnings call?
Arthneeti's analysis of the Q2 FY27 earnings call covers revenue, margins, capex and fundraising guidance from Rubicon Research's management.
How does Arthneeti AI analyse Rubicon Research?
Arthneeti reads Rubicon Research's earnings call transcripts and filings and scores revenue growth, margins, capex and fundraising, then ranks the company against its sector.
Continue your research
What Rubicon Research's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Themis Medicare (Q2 FY27)
Q2 FY27 net revenue: ₹89.74 crore, up 15.1% year-on-year from ₹77.99 crore in Q2 FY26 (Page 8). Key investor presentation takeaways from Themis Medicare Ltd's Q
- Panacea Biotec (Q2 FY27)
September 30, 2026: ₹18,967 Lakh . Key results statement takeaways from Panacea Biotec Ltd's Q2 FY27 results statement — and how it ranks against sector peers.
- Biofil Chemicals (Q2 FY27)
Quarterly Revenue (Q2 ended 30/09/2026):** ₹166.87 Lakhs (Pharma Unit), ₹0.00 Lakhs (Chemicals Division); Total Gross Turnover ₹166.87 Lakhs. Key results statem
- Alpa Laboratorie (Q2 FY27)
Standalone: ₹3,097.56 lacs . Key results statement takeaways from Alpa Laboratories Ltd's Q2 FY27 results statement — and how it ranks against sector peers.
